Wella FY 2003
This article was originally published in The Rose Sheet
Executive Summary
Cosmetics & Fragrances division sales are anticipated to grow 15.3% when adjusted for currency and 9% on a nominal basis, German hair care company says in fiscal 2003 preliminary report. Overall consolidated sales were $4.2 bil. (€1= $1.26), an increase of 4.3% adjusted for currency, but down 2.3% on a nominal basis. Earnings will be impacted by negative foreign currency effects, Wella noted. Operating income will be "slightly lower" at $394.7 mil., the firm said, but profit before taxes will be $301.4 mil., a "slight improvement" over prior-year results of $300.3 mil. Commenting on the effects of last year's acquisition by Procter & Gamble, Wella notes that despite "prevailing uncertainty among clients and employees associated with a takeover process, the company is satisfied with this performance." The firm will release complete FY 2003 results on March 4...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.